Blood-Based Molecular Testing For Pancreatic Cancer Patients

[ad_1]

Molecular profiling of the tumor itself should remain the gold standard.

A new study published in the just-published “Oncotarget” peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue biopsies. Further refinement in defining the optimal patient population and timing of blood sampling may improve the value of a blood-based test.” The study was conducted by a team of researchers and clinicians from Perthera, Inc., a precision medicine company based in McLean, VA, the Pancreatic Cancer Action Network (PanCAN), Lombardi Comprehensive…

[ad_2]

Read the full article from the Source…

Back to Top